Reported cases of late-onset neutropenia
Patient no. . | Age, y . | Sex . | Diagnosis . | Total regimens, no. . | Time to LON, d . | ANC nadir, × 109/L . | Duration of LON, d . | Clinical presentation . | Filgrastim . |
|---|---|---|---|---|---|---|---|---|---|
| 1* | 49 | F | FL | 3 | 168 | .150 | 14 | Buccal cellulitis | No |
| 1* | 51 | F | FL | 5 | 61 | .040 | 5 | Buccal cellulitis | Yes |
| 2 | 84 | F | FL | 4 | 65 | .200 | 9 | Routine CBC | No |
| 3 | 73 | F | MCL | 4 | 122 | .100 | 148 | Routine CBC | Yes |
| 4 | 63 | F | DLBCL | 5 | 153 | .400 | 140 | Routine CBC | Yes |
| 5 | 40 | M | FL | 3 | 105 | .190 | 4 | Pneumonia | No |
| 6 | 32 | M | CML | 3 | 150 | .000 | 9 | Routine CBC | Yes |
| 7 | 47 | M | MCL | 3 | 32 | .200 | 7 | Routine CBC | No |
| 8 | 51 | M | FL | 3 | 133 | .040 | 3 | Febrile | Yes |
| 9 | 70 | F | DLBCL | 1 | 119 | .060 | 3 | Afebrile | Yes |
| 10 | 38 | F | FL | 1 | 91 | .020 | 5 | Febrile | Yes |
| 11 | 54 | M | CLL | 5 | 56 | .135 | 6 | Afebrile | Yes |
| 12 | 73 | M | FL | 3 | 140 | .100 | 6 | Afebrile | No |
| 13 | 53 | M | DLBCL | 3 | 161 | .397 | 20 | Afebrile | No |
| 14 | 63 | F | FL | 3 | 105 | .312 | 12 | Afebrile | No |
| 15 | 56 | M | FL | 3 | 49 | .095 | NA | Febrile | No |
| 16 | 44 | M | DLBCL | 2 | 84 | .160 | 8 | Febrile | Yes |
| 17 | 50 | M | DLBCL | 2 | 145 | .140 | 9 | Febrile | No |
| 18 | 55 | F | DLBCL | 2 | 173 | .420 | 93 | Afebrile | No |
| 19 | 55 | F | DLBCL | 2 | 193 | .090 | 8 | Febrile | Yes |
| 20 | 52 | F | DLBCL | 2 | 156 | .420 | 9 | Cellulitis | Yes |
| 21 | 63 | F | DLBCL | 2 | 161 | .120 | 16 | Diarrhea and hypotension | No |
| Median | 54 | NA | NA | 3 | 128 | .138 | 11† | NA | NA |
Patient no. . | Age, y . | Sex . | Diagnosis . | Total regimens, no. . | Time to LON, d . | ANC nadir, × 109/L . | Duration of LON, d . | Clinical presentation . | Filgrastim . |
|---|---|---|---|---|---|---|---|---|---|
| 1* | 49 | F | FL | 3 | 168 | .150 | 14 | Buccal cellulitis | No |
| 1* | 51 | F | FL | 5 | 61 | .040 | 5 | Buccal cellulitis | Yes |
| 2 | 84 | F | FL | 4 | 65 | .200 | 9 | Routine CBC | No |
| 3 | 73 | F | MCL | 4 | 122 | .100 | 148 | Routine CBC | Yes |
| 4 | 63 | F | DLBCL | 5 | 153 | .400 | 140 | Routine CBC | Yes |
| 5 | 40 | M | FL | 3 | 105 | .190 | 4 | Pneumonia | No |
| 6 | 32 | M | CML | 3 | 150 | .000 | 9 | Routine CBC | Yes |
| 7 | 47 | M | MCL | 3 | 32 | .200 | 7 | Routine CBC | No |
| 8 | 51 | M | FL | 3 | 133 | .040 | 3 | Febrile | Yes |
| 9 | 70 | F | DLBCL | 1 | 119 | .060 | 3 | Afebrile | Yes |
| 10 | 38 | F | FL | 1 | 91 | .020 | 5 | Febrile | Yes |
| 11 | 54 | M | CLL | 5 | 56 | .135 | 6 | Afebrile | Yes |
| 12 | 73 | M | FL | 3 | 140 | .100 | 6 | Afebrile | No |
| 13 | 53 | M | DLBCL | 3 | 161 | .397 | 20 | Afebrile | No |
| 14 | 63 | F | FL | 3 | 105 | .312 | 12 | Afebrile | No |
| 15 | 56 | M | FL | 3 | 49 | .095 | NA | Febrile | No |
| 16 | 44 | M | DLBCL | 2 | 84 | .160 | 8 | Febrile | Yes |
| 17 | 50 | M | DLBCL | 2 | 145 | .140 | 9 | Febrile | No |
| 18 | 55 | F | DLBCL | 2 | 173 | .420 | 93 | Afebrile | No |
| 19 | 55 | F | DLBCL | 2 | 193 | .090 | 8 | Febrile | Yes |
| 20 | 52 | F | DLBCL | 2 | 156 | .420 | 9 | Cellulitis | Yes |
| 21 | 63 | F | DLBCL | 2 | 161 | .120 | 16 | Diarrhea and hypotension | No |
| Median | 54 | NA | NA | 3 | 128 | .138 | 11† | NA | NA |
Series nos. 1 to 710 ; series nos. 8 to 1511 ; and series nos. 16 to 21.12
FL indicates follicular lymphoma; CBC, complete blood count; MCL, mantle cell lymphoma; DLBCL, diffuse large B- cell lymphoma; CML, chronic myelogenous leukemia; CLL, chronic lymphocytic leukemia; and NA, not applicable.
Patient 1 presented twice with LON following separate courses of rituximab.
Median duration of LON in patients who did not receive filgrastim.